European Network of Excellence for Big Data in Hematology. Funded by the Innovative Medicines Initiative. Read more
Registration of novel drug compounds is increasingly difficult, costly, and time-consuming, thus preventing patients from receiving the right treatment in time. Patients with hematologic malignancies (HMs) have unmet needs that must be addressed. Read more
51 Partners sharing the same goal: use ‘big data’ technologies to deliver information that will help to improve the care of patients with hematological malignancies: Introducing the HARMONY Alliance. Read more
Europe's largest public-private partnership aiming to improve the outcomes of patients with hematological malignancies through the use of big data sharing among all relevant stakeholders involved.
@HARMONY Talks: Partners, Work Package Leaders and Leaders of the HM Disease Groups are sharing their views and experiences.
Read moreHARMONY
Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
Funded through the Innovative Medicines Initiative (IMI) 2 Joint Undertaking and listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Login
